Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
Banks Pivot Toward Greener Finance in Climate Action Push - Bloomberg

2018-07-12 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AXAHF AXAHY NTXFF UBS CS UBS.PRDCL KN NTXFY AXJ ULSGF

12
Ex-State Street executive convicted in U.S. of hidden fee fraud | Reuters

2018-06-26 reuters
BOSTON (Reuters) - A former State Street Corp (STT.N) executive was convicted on Tuesday of participating in a scheme to defraud several of the bank’s customers by charging them secret commissions on billions of dollars of trades.
STT AXAHF AXAHY STT.PRC CS STT.PRE STT.PRD STT.PRG AXJ

12
Ex-State Street exec pulled 'bait-and-switch' on clients: US prosecutor

2018-06-25 channelnewsasia
A former State Street Corp executive engaged in "bait-and switch" by promising to charge several of the bank's clients low fees to execute billions of dollars of trades before secretly applying commissions to them, a U.S. prosecutor said on Monday.
STT AXAHF AXAHY STT.PRC CS STT.PRE STT.PRD STT.PRG AXJ

12
Ex-State Street exec pulled 'bait-and-switch' on clients -U.S. prosecutor

2018-06-25 reuters
BOSTON (Reuters) - A former State Street Corp (STT.N) executive engaged in “bait-and switch” by promising to charge several of the bank’s clients low fees to execute billions of dollars of trades before secretly applying commissions to them, a U.S. prosecutor said on Monday.
STT AXAHF AXAHY STT.PRC CS STT.PRE STT.PRD STT.PRG AXJ

1
AXA Equitable Holdings (EQH) CEO Mark Pearson on Q1 2018 Results - Earnings Call Transcript

2018-06-20 seekingalpha
Good morning. My name is Mitchell and I will be your conference operator today. At this time, I would like to welcome everyone to the AXA Equitable Holdings Inc. First Quarter 2018 Results. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions].
AXAHF AXAHY CS EQH DTK AXJ

176
Allianz’s deal hunt keeps mart guessing

2018-06-12 bworldonline
Europe’s largest insurer, Allianz SE, is in the early stages of evaluating a variety of potential acquisition targets as deal-hungry Chief Executive Officer Oliver Baete scans the market for growth, people with knowledge of the matter said. Those on the list range from Switzerland’s Zurich Insurance Group AG and the UK’s RSA Insurance Group Plc to Hartford Financial Services Group Inc. in the US or, going further afield, assets in China, they said.
VR C.WSA ALIZF AXJ QBIEY ARGO UBS.PRDCL HGH 8685 ZFSVF AVF AIG QBEIF ZURVY CGBBW AHL RSAB XLGLF AXAHF NRDEF CS XL VR.PRA VR.PRB HIG.WS AHL.PRB AHL.PRC C.WS.B AXAHY AHL.PRA UBS HIG C.WS.A C.PRP C.PRU RSAIF NRBAY AZSEY AHL.PRD RSA C.PRS AGIIL C.PRL C C.PRJ C.PRK C.PRG AGII C.PRC QBE RSNAY AIG.WS C.PRPCL ULSGF

12
Ex-State Street executive cheated clients with secret fees: U.S. prosecutor

2018-06-05 reuters
BOSTON (Reuters) - A former State Street Corp (STT.N) executive directed a fraudulent scheme to overcharge several of the bank’s clients, including Kuwait’s sovereign wealth fund, by applying secret commissions to billions of dollars’ worth of trades, a U.S. prosecutor told jurors on Tuesday.
STT AXAHF AXAHY STT.PRC CS STT.PRE STT.PRD STT.PRG AXJ

12
Ex-State Street executive cheated clients with secret fees: US prosecutor - Channel NewsAsia

2018-06-05 channelnewsasia
A former State Street Corp executive directed a fraudulent scheme to overcharge several of the bank's clients, including Kuwait's sovereign wealth fund, by applying secret commissions to billions of dollars' worth of trades, a U.S. prosecutor told jurors on Tuesday.
STT AXAHF AXAHY STT.PRC CS STT.PRE STT.PRD STT.PRG AXJ

12
Ex-State Street executive cheated clients with secret fees: U.S. prosecutor

2018-06-05 reuters
BOSTON, June 5 (Reuters) - A former State Street Corp executive directed a fraudulent scheme to overcharge several of the bank’s clients, including Kuwait’s sovereign wealth fund, by applying secret commissions to billions of dollars’ worth of trades, a U.S. prosecutor told jurors on Tuesday.
STT AXAHF AXAHY STT.PRC CS STT.PRE STT.PRD STT.PRG AXJ

2
Is iShares Edge MSCI Multifactor Intl ETF (INTF) a Hot ETF Right Now?

2018-05-17 zacks
The iShares Edge MSCI Multifactor Intl ETF (INTF - Free Report) made its debut on 04/28/2015, and is a smart beta exchange traded fund that provides broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
AXAHF VEA AXAHY 6501 VEU CS AXJ HTHIY

107
U.S. IPO Weekly Recap: AXA Is Year's Largest IPO, But Chinese Tech Steals The Show

2018-05-12 seekingalpha
This week featured the largest IPO of 2018, AXA Equitable (NYSE:EQH). Yet, another spin-off stole the show, as fast-growing Chinese tech company Huya (NYSE:HUYA) popped 34%.
ABP AXAHF ARMO HUYA CS EQH LLY AXJ YY AXAHY SPOT EVLO OBNK SNAP

1
AXA Equitable Flops in Largest IPO of the Year - WSJ

2018-05-10 wsj
The largest initial public offering of the year received a weak reception from investors as shares of insurer AXA Equitable Holdings Inc. made their debut Thursday at a price well below earlier expectations, showing that recent strength in the new-issue market is largely confined to the technology sector.
AXAHF AXAHY CS EQH DTK AXJ

7
French insurer Axa finds tepid appetite for US business as IPO comes up $1 billion short

2018-05-10 cnbc
Axa SA's $15.3 billion takeover of global property casualty firm XL Group was a monster deal in the insurance world, but Paris-based Axa's plan to pay for the acquisition has come up short.
PRU AXAHF CS PFK LNC.WS DTK XL AXJ AXAHY LNC PRH XLGLF PJH

14
UPDATE 1-AXA's U.S. arm raises $2.75 bln in IPO, misses target -source

2018-05-09 reuters
(Reuters) - French insurer AXA SA’s (AXAF.PA) initial public offering (IPO) of its U.S. division raised $2.75 billion by pricing at $20 per share on Wednesday, below its targeted range of $24-27 per share, a person familiar with the matter said.
AXAHF CS MS.PRE MS.PRF XL MS.PRG MS.PRA AXJ AXAHY GSHD MS.PRI MS.PRK XLGLF MS

1
AXA's U.S. arm raises $2.75 bln in IPO, misses target -source

2018-05-09 reuters
May 9 (Reuters) - French insurer AXA SA’s initial public offering (IPO) of its U.S. division priced at $20 per share on Wednesday, below its targeted range of $24-27 per share, raising about $2.75 billion, a person familiar with the matter said.
AXAHF AXAHY CS AXJ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

16h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

17h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EPA:CS / AXA on message board site Silicon Investor.

Politics for Pros- moderated Mainstream Politics and Economics
Immunomedics (IMMU) - moderated Plastics to Oil - Pyrolysis and Secret Catalysts and Alterna
Politics for Conservatives Robotics and Artificial Intelligence
Quantum Economics.......2012 and Beyond Hurricanes: Tracking and Economics
Cisco Systems, Inc. (CSCO) Decision Diagnostics Corp (OTC: DECN)